GlassScriptPhysician profile
Mariel M Velez
NPI 1427347053
$2,413.20
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $20.75 · 2021: $23.09 · 2022: $136 · 2023: $26.15 · 2024: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $928.56 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $200.68 | 2019 | |
| Neuropace, INC. | $199.96 | 2024 | |
| Greenwich Biosciences, INC. | $177.28 | 2019 | |
| Eisai INC. | $174.15 | 2019 | |
| Amgen INC. | $173.99 | 2019 | |
| Medtronic USA, INC. | $136.23 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $135.77 | 2022 | |
| Ucb, INC. | $104.01 | 2019 | |
| Adamas Pharmaceuticals, INC. | $51.92 | 2019 | |
| Philips North America LLC | $40.45 | 2019 | |
| Sk Life Science, INC. | $23.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.52 | 2019 | |
| Aquestive Therapeutics, INC. | $18.21 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.65 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariel Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.